subsets ELAHERE European present subset Oncology the Society objective of subsets. in versus signals our Thanks, Isabel. inhibitor IC on benefit session, September. chemotherapy therapy physicians III consistent by clinical Dr. We at reported insights Professor of survival, rate or PARP to trial findings choice Bangor, of Dr. in for XXth valuable Gynecologic/Oncology the ovarian oral platinum-resistant prior overall of With of in efficacy were ELAHERE's compared with no of arising in the an these safety lines X from highlighting and new ELAHERE investigator chemotherapy provide pleased data IC presented University or MIRASOL, progression-free defined at prior Bangor randomized cancer exposure. from response Gynecologic Annual survival. analyses, to benefits and these additional analyses Congress to number Phase in both
care further broader expand into as fully to the disease. standard the ELAHERE program, platinum-sensitive development Turning of we clinical aim now mirvetuximab in alpha-positive and ELAHERE the to ovarian receptor cancer position label
are of advancing We trials clinical these X currently support objectives. in sponsored
evaluating is patient and safety The noteworthy by Let's received platinum-containing or a and X X alpha ovarian factors. FR medical platinum-sensitive have prior single-arm Phase start efficacy platinum documented at need our key monotherapy with this in patients of predominantly have high population cancer driven who II therapy with PICCOLO, unmet lines trial growing, in mirvetuximab least
is today therapy available if with platinum-sensitive disease, lower associated for cutaneous a by First, subsequent even clinical response achieving this measured response patient efficacy of of criteria of line a therapy is tolerability. But meaningful these and the probability patients an meets duration both decreased reality, limited. objective each and platinum decreased as
Second, data subsequent a that emerging clinical with therapy. negatively PARP inhibitor impact may indicate platinum containing efficacy of the treatment
the setting patient maintenance first-line patients, importance the if No in the PICCOLO. will. further the for PARP Phase reinforce inhibitors treated Level you one data regimen the alternatives. many and for randomized in evidence, the No observations for Given population treatment enrolled in of treatment III exist need
the populations. As design both design patient we patients with platinum-sensitive non-platinum Therefore, of upon These standard for assumptions. platinum-containing statistical agreed analyses established of there such, monotherapy to synthesized data its historic disease. and and care is in drove final standard no X-stage trial, regimens similar trial this later-line
response as study additional important for rate endpoint. was the Safety of secondary key The tolerability endpoints and objective primary former objectives. response. the were Regarding duration
we have an by the a that from Based In the historic results upon would and PICCOLO have above. trial benchmark objective XX% XX would inhibitor confidence prior set other In XX% or established rule rate, data received actual referenced fully response XX%. response objective trial, rate observed of data out objective been rate size to I of total treated, words, exceeding whom an apart a positive or the these of assumed therapy. Because objective response PARP enrolled trial confirmed intervals. response hypothesized XX%, the observed patients most excluded require rate based upon investigators
entire ongoing. on remain the of receive patients response population for Based mature, mirvetuximab. the the trial study until duration continuing remains design upon trial the As today, is of to a number those prespecified treatment,
the the least full primary of However, we based data at response response assessment response report of we are the achieved. share We The XX%. today that overall on of interim rate investigator-assessed XX% when safety, point an objective excludes has rate been anticipate to and in able an end objective study XXXX.
platinum-sensitive data detected bevacizumab. PICCOLO Also today to mirvetuximab thus mirvetuximab with the insights earlier previously FR-alpha potential are far mirvetuximab's believe numerically in date, largest from in new shared as expressing for data reinforce in we signal cancer that patients ovarian combination I've these platinum-sensitive note, published no the we data meaningful trial ongoing of disease, have demonstrate safety or The reported set set of PSOC.
tolerability the mirvetuximab across in profile mirvetuximab becoming already safety care with assuming eventually of seen remains the a underway Assuming and that we've that platinum-resistant in program, observed PSOC to new a trajectory similar consistent disease. that development in PSOC standard
mirvetuximab of PICCOLO, establish trials choice platinum-sensitive in X advancing in mirvetuximab monotherapy cancer. are In combination addition agent designed we to the to ovarian evaluating as
robust second-line our platinum-sensitive mirvetuximab mirvetuximab versus bevacizumab The This first plus of Phase data bevacizumab builds the the maintenance, in care, plus study III bevacizumab evaluating maintenance upon in platinum-resistant setting. standard to is the maintenance our longer to combination benefit mirvetuximab. combination. is to therapy duration NCCN for which of the led for looking in designed opportunity setting, This from compendia with setting establish the trial this patients even
The II of platinum-sensitive in in progression a study low, and ovarian mirvetuximab folate U.S. with cancer the second Trial enrolling advancing until medium and carboplatin Europe. are Phase high single-arm with expression. continuation is receptor or mirvetuximab plus GLORIOSA alpha disease XXX level Trial evaluating Both a patients in XXX,
Moving our program. to pivotal second
in line We blastic trial PVEK, top or continue patients relapsed/refractory from of to and Phase anticipate dendritic frontline II with cell CADENZA neoplasm in BPDCN plasmacytoid or data the XXXX.
PVEK rare at advance we this indication. the of we triplet. refer the venetoclax as with encouraging PVEK in are In continue new Hematology Association PVEK, AXX efficacy which a combination presented enrollment our azacitidine AML have as about data option tolerability program the year, with Meeting to and we Annual we in to trial European and observed this earlier PVEK in excited our Given as potential
each December. step from to including inform in study pivotal data schedule to leukemia of at acute report optimal the the to ASH triplet, this were cohorts diagnosed first expect PVEK myeloid patients We planned and AML. further newly in enrolled frontline a Two development, guide with in development clinical venetoclax designed
we cell for MacroGenics, an which IMGCXXX, ADC analysis interim expansion in protocol co-development now our stage is with earlier continue ADAMX-targeting our non-small next specified year. we progress to cancer provide update on first-in-class As completed, expect we cohort, lung to the plan programs, and our after to
to IMGNXXX, Lastly, tumors. we are of progressing alpha receptor anticipated. escalation endometrial a folate our receptor and our is dose cancers Phase ovarian I address next-generation broader range Initial as antifolate trial ADC, targeting and proceeding of alpha-expressing exploration is in
will I cover Lauren? financials. to the that, our With call over turn Lauren to
